Sai Life Sciences Limited
Dec 11, 2024 - Dec 13, 2024
Sai Life Sciences Limited IPO Details
Mainline
Status
listed
Issue Price
₹522.00 - ₹549.00
Lot Size
27 Shares
Subscription
10.27 times
Listing Price
₹650.00 (18.4%)
Face Value
₹1 Per share
Issue Size
Approx ₹3042.62 Cr
Fresh Issue
Approx ₹950 Cr
Total Shares Offered
Approx ₹2092.62 Cr
Retail Quota
35%
QIB Quota
50%
HNI Quota
15%
Retail Approx
-
S-HNI Approx
-
B-HNI Approx
-
Issue Type
Book Built Issue IPO
Listing On
BSE, NSE
Registrar
Kfin Technologies Limited
NSE Code
SAILIFE
BSE Code
544306
IPO Tentative Timetable
Open Date
Wed Dec 11 2024
Close Date
Fri Dec 13 2024
Allotment Date
Mon Dec 16 2024
Refunds Initiation
Tue Dec 17 2024
Demat Transfer
Tue Dec 17 2024
Listing Date
Wed Dec 18 2024
Valuation
Earning Per Share (EPS)
₹4.57
Price/Earning P/E Ratio
N/A
Return on Net Worth (RoNW)
8.50%
Net Asset Value (NAV)
₹53.83
Promoters
Pre issue Share Holding
40.48%
Post issue Share Holding
-
Company Promoters
- Kanumuri Ranga Raju
- Krishnam Raju Kanumuri
- Kanumuri Mytrey
- Sai Quest Syn Private Limited
- Sunflower Partners
- Lily Partners
- Marigold Partners
- Tulip Partners
Lead Managers
Kotak Mahindra Capital Company Limited
Jefferies India Private Limited
Morgan Stanley India Company Pvt Ltd
Iifl Securities Ltd
Live Subscription
| Date | QIB | NII | NII (> ₹10L) | NII (< ₹10L) | Retail | Total |
|---|---|---|---|---|---|---|
| Dec 11, 2024 | 2.52 | 0.16 | 0.15 | 0.17 | 0.19 | 0.85 |
| Dec 12, 2024 | 3.2 | 0.6 | 0.59 | 0.63 | 0.43 | 1.26 |
| Dec 13, 2024 | 29.78 | 4.99 | 6.1 | 2.78 | 1.39 | 10.27 |
Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 27 | ₹14,823 |
| Retail (Max) | 13 | 351 | ₹192,699 |
| S-HNI (Min) | 14 | 378 | ₹207,522 |
| S-HNI (Max) | 67 | 1,809 | ₹993,141 |
| B-HNI (Min) | 68 | 1,836 | ₹1,007,964 |
Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 11.79% |
| ROCE | 15.96% |
| RoNW | 8.13% |
| P/BV | 10.18 |
| PAT Margin (%) | 5.65 |
IPO Reservation
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | 1,66,26,336 (30%) | NA |
| QIB Shares Offered | 1,10,84,225 (20%) | NA |
| NII (HNI) Shares Offered | 83,13,168 (15%) | - |
| bNII > ₹10L | 55,42,113 (10%) | 14,661 |
| sNII < ₹10L | 27,71,056 (5%) | 7,330 |
| Retail Shares Offered | 1,93,97,392 (35%) | 7,18,421 |
| Total Shares Offered | 5,54,21,121 (100%) | - |
Company Financial
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 2,476.78 | 2,275.14 | 2,186.65 | 2,164.23 |
| Revenue | 693.35 | 1,494.27 | 1,245.11 | 897.74 |
| Profit After Tax | 28.01 | 82.81 | 9.99 | 6.23 |
| Net Worth | 1,044.75 | 974.34 | 887.29 | 877.76 |
| Reserves and Surplus | 855.69 | 953.99 | 867.43 | 859.17 |
| Total Borrowing | 764.49 | 710.16 | 699.23 | 751.32 |
About Company
Sai Life Sciences Limited, established in January 1999, specializes in researching, developing, and manufacturing small-molecule chemical compounds. It provides customized services to biotech companies and global pharmaceutical firms.
In the financial year 2024, and particularly in September 2024, the company served over 280 pharmaceutical innovators, including more than 230 in that single month. Among these were 18 of the top 25 pharmaceutical companies by 2023 revenue. Sai Life Sciences operates in countries like the US, the UK, Europe, and Japan.
The company’s business development team has 16 skilled professionals, with six based in the US, nine in the UK and Europe, and one in Japan.
It offers services in:
- Chemistry, Manufacturing, and Control (CMC) through contract development and manufacturing organizations (CDMO).
- Contract research organization (CRO) services, including integrated drug discovery in biology, chemistry, and drug metabolism and pharmacokinetics (DMPK).
As of September 2024, the company had 2,353 scientific staff, with most holding advanced degrees, including 302 with PhDs and 1,475 with master’s degrees. The total workforce stood at 3,135 employees, covering all areas of the CRDMO value chain.
Key strengths of the company include:
- Integrated CRDMO services that support discovery, development, and manufacturing.
- CRO services with expertise in biology, chemistry, and DMPK.
- A CDMO platform handling a wide range of commercial and developmental molecules.
In the financial year 2024, and particularly in September 2024, the company served over 280 pharmaceutical innovators, including more than 230 in that single month. Among these were 18 of the top 25 pharmaceutical companies by 2023 revenue. Sai Life Sciences operates in countries like the US, the UK, Europe, and Japan.
The company’s business development team has 16 skilled professionals, with six based in the US, nine in the UK and Europe, and one in Japan.
It offers services in:
- Chemistry, Manufacturing, and Control (CMC) through contract development and manufacturing organizations (CDMO).
- Contract research organization (CRO) services, including integrated drug discovery in biology, chemistry, and drug metabolism and pharmacokinetics (DMPK).
As of September 2024, the company had 2,353 scientific staff, with most holding advanced degrees, including 302 with PhDs and 1,475 with master’s degrees. The total workforce stood at 3,135 employees, covering all areas of the CRDMO value chain.
Key strengths of the company include:
- Integrated CRDMO services that support discovery, development, and manufacturing.
- CRO services with expertise in biology, chemistry, and DMPK.
- A CDMO platform handling a wide range of commercial and developmental molecules.
Company Contact
sai life sciences limited plot no. ds-7, ikp knowledge park turkapally village, shameerpet mandal, malkajgiri district, hyderabad-500078
Phone: +9140 6815 6000
Email: investors@sailife.com
Website: https://www.sailife.com/
Registrar Contact
kfin technologies limited
Phone: 04067162222, 04079611000
Email: sailifesciences.ipo@kfintech.com